Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsUsing the structure provided by the well-described cancer–immunity cycle, scientists outline the key steps required for a successful antitumour immune response in the context of renal cell carcinoma, and describe the development of promising new immunotherapies within the context of this framework.
[Nature Reviews Clinical Oncology]
6445218 {6445218:8EATWYWD} apa 50 1 157879 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-8a9fb0e8cb3947254bb522e03160e91b%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%228EATWYWD%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Braun%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBraun%2C%20D.%20A.%2C%20Bakouny%2C%20Z.%2C%20Hirsch%2C%20L.%2C%20Flippot%2C%20R.%2C%20Van%20Allen%2C%20E.%20M.%2C%20Wu%2C%20C.%20J.%2C%20%26amp%3B%20Choueiri%2C%20T.%20K.%20%282021%29.%20Beyond%20conventional%20immune-checkpoint%20inhibition%20%26%23x2014%3B%20novel%20immunotherapies%20for%20renal%20cell%20carcinoma.%20%3Ci%3ENature%20Reviews%20Clinical%20Oncology%3C%5C%2Fi%3E%2C%201%26%23x2013%3B16.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-020-00455-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-020-00455-z%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3D8EATWYWD%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Beyond%20conventional%20immune-checkpoint%20inhibition%20%5Cu2014%20novel%20immunotherapies%20for%20renal%20cell%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziad%22%2C%22lastName%22%3A%22Bakouny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronan%22%2C%22lastName%22%3A%22Flippot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliezer%20M.%22%2C%22lastName%22%3A%22Van%20Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20J.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toni%20K.%22%2C%22lastName%22%3A%22Choueiri%22%7D%5D%2C%22abstractNote%22%3A%22The%20management%20of%20advanced-stage%20renal%20cell%20carcinoma%20%28RCC%29%20has%20been%20transformed%20by%20the%20development%20of%20immune-checkpoint%20inhibitors%20%28ICIs%29.%20Nonetheless%2C%20most%20patients%20do%20not%20derive%20durable%20clinical%20benefit%20from%20these%20agents.%20Importantly%2C%20unlike%20other%20immunotherapy-responsive%20solid%20tumours%2C%20most%20RCCs%20have%20only%20a%20moderate%20mutational%20burden%2C%20and%20paradoxically%2C%20high%20levels%20of%20tumour%20CD8%2B%20T%20cell%20infiltration%20are%20associated%20with%20a%20worse%20prognosis%20in%20patients%20with%20this%20disease.%20Building%20on%20the%20successes%20of%20antibodies%20targeting%20the%20PD-1%20and%20CTLA4%20immune%20checkpoints%2C%20multiple%20innovative%20immunotherapies%20are%20now%20in%20clinical%20development%20for%20the%20treatment%20of%20patients%20with%20RCC%2C%20including%20ICIs%20with%20novel%20targets%2C%20co-stimulatory%20pathway%20agonists%2C%20modified%20cytokines%2C%20metabolic%20pathway%20modulators%2C%20cell%20therapies%20and%20therapeutic%20vaccines.%20However%2C%20the%20successful%20development%20of%20such%20novel%20immune-based%20treatments%20and%20of%20immunotherapy-based%20combinations%20will%20require%20a%20disease-specific%20framework%20that%20incorporates%20a%20deep%20understanding%20of%20RCC%20immunobiology.%20In%20this%20Review%2C%20using%20the%20structure%20provided%20by%20the%20well-described%20cancer%5Cu2013immunity%20cycle%2C%20we%20outline%20the%20key%20steps%20required%20for%20a%20successful%20antitumour%20immune%20response%20in%20the%20context%20of%20RCC%2C%20and%20describe%20the%20development%20of%20promising%20new%20immunotherapies%20within%20the%20context%20of%20this%20framework.%20With%20this%20approach%2C%20we%20summarize%20and%20analyse%20the%20most%20encouraging%20targets%20of%20novel%20immune-based%20therapies%20within%20the%20RCC%20microenvironment%2C%20and%20review%20the%20landscape%20of%20emerging%20antigen-directed%20therapies%20for%20this%20disease.%22%2C%22date%22%3A%222021-01-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41571-020-00455-z%22%2C%22ISSN%22%3A%221759-4782%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41571-020-00455-z%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-01-13T00%3A52%3A32Z%22%7D%7D%5D%7D
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021). Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 1–16. https://doi.org/10.1038/s41571-020-00455-z Cite
